Edition:
India

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

23.59USD
19 Jan 2018
Change (% chg)

$1.84 (+8.46%)
Prev Close
$21.75
Open
$22.02
Day's High
$25.13
Day's Low
$22.02
Volume
395,810
Avg. Vol
164,574
52-wk High
$25.13
52-wk Low
$3.83

Latest Key Developments (Source: Significant Developments)

GlycoMimetics qtrly loss per share $‍0.24
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and third quarter 2017 results.Glycomimetics inc - ‍phase 3 clinical trial of rivipansel on track for completion in second half of 2018​.Glycomimetics inc qtrly loss per share $‍0.24​.Glycomimetics inc - ‍research and development expenses decreased slightly to $5.8 million for quarter ended september 30, 2017 as compared to $5.9 million​.  Full Article

GlycoMimetics reports qtrly loss per share of $0.41
Friday, 5 Aug 2016 

GlycoMimetics Inc : GlycoMimetics reports second quarter 2016 results . Qtrly loss per share $0.41 .Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article

Glycomimetics announces pricing of public offering
Friday, 17 Jun 2016 

Glycomimetics Inc : Says public offering of 3.30 million common shares priced at $6.10 per share .Glycomimetics announces pricing of public offering of common stock.  Full Article

Glycomimetics announces proposed public offering of common stock
Friday, 17 Jun 2016 

Glycomimetics : Glycomimetics announces proposed public offering of common stock .Intends to use proceeds to conduct planned clinical trials of GMI-1271, to fund research and development of preclinical pipeline, including drug discovery.  Full Article

Glycomimetics' GMI-1271 yields high remission rates in phase 1 portion of phase 1/2 clinical trial for AML
Friday, 10 Jun 2016 

Glycomimetics' Gmi : Dose escalation is complete and a GMI-1271 dose was identified for phase 2 testing . Results, showed an overall response rate of 47 percent among 19 patients .1271 yields high remission rates and favorable tolerability in phase 1 portion of phase 1/2 clinical trial for AML.  Full Article

BRIEF-GlycoMimetics qtrly loss per share $‍0.24

* Glycomimetics reports program updates and third quarter 2017 results